Clinical trials: Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Condition Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Funder type Industry (pharma, biotech, devices)
Extrapulmonary Neuroendocrine Cancer (epNEC)
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves…
- Trial name
- NCT07544654
- Testing
- Obrixtamig, Carboplatin, Etoposide
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim